Gilead & Merck: Once-weekly islatravir/lenacapavir (ISL/LEN) maintained viral suppression in Phase 3 ISLEND trials

Key highlights
  • ISL/LEN is a once-weekly single tablet containing islatravir 2 mg and lenacapavir 300 mg.
  • ISLEND-1 Week 48: 0% of participants who switched to ISL/LEN had HIV-1 RNA ≥50 copies/mL versus 0.3% who remained on BIKTARVY (FDA snapshot).
  • ISLEND-2 Week 48: 0.3% on ISL/LEN had HIV-1 RNA ≥50 copies/mL versus 1.3% on standard-of-care regimens (FDA snapshot).
  • Safety was generally similar: ISLEND-1 treatment-related AEs 13.5% (ISL/LEN) vs 13.2% (BIKTARVY); serious AEs and discontinuations were low in both trials.

Trials and design

Two multicenter Phase 3 trials (ISLEND-1 and ISLEND-2) evaluated a once-weekly single-tablet regimen of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) in adults with virologic suppression on stable antiretroviral therapy for ≥6 months. ISLEND-1 was randomized, double-blind and active-controlled versus BIKTARVY; ISLEND-2 was randomized, open-label and active-controlled versus participants’ standard-of-care daily regimens. Participants received initial doses on Day 1 and Day 2 followed by once-weekly dosing from Day 8 to Week 96. The primary endpoint was the proportion with HIV-1 RNA ≥50 copies/mL at Week 48 by the FDA-defined Snapshot algorithm.

Key efficacy results at Week 48

Both trials met the primary endpoint for noninferiority. In ISLEND-1, 0% of participants who switched to ISL/LEN had HIV-1 RNA ≥50 copies/mL at Week 48 versus 0.3% on BIKTARVY. In ISLEND-2, 0.3% on ISL/LEN versus 1.3% on standard-of-care had HIV-1 RNA ≥50 copies/mL. These outcomes will be presented at AIDS 2026 and are intended to support regulatory submissions.

Safety, tolerability and patient-reported outcomes

Safety profiles were generally similar to comparators. ISLEND-1 reported treatment-related AEs in 13.5% (ISL/LEN) versus 13.2% (BIKTARVY); common AEs included nausea and headache (~3%). Serious AEs and discontinuations were low in both arms. ISLEND-2 reported treatment-related AEs of 18% with ISL/LEN versus <1% with standard of care; common ISL/LEN AEs included headache (5%), nausea (3%) and diarrhea (3%). CD4+ T-cell and lymphocyte counts and body weight remained stable through Week 48, and no discontinuations were attributed to CD4/lymphocyte declines. Participants switching to ISL/LEN reported higher treatment satisfaction and lower treatment burden. ISL/LEN is investigational and not approved for use.

Source: Merck

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

15 July 2026
Merck to present daily, weekly and monthly HIV data at AIDS 2026

Late‑breakers include Week 48 results for once‑weekly islatravir+lenacapavir and Week 24 data for islatravir+ulonivirine; once‑monthly PrEP trials are enrolling.

8 June 2026
Merck and Gilead discontinue Phase 3 KEYNOTE‑D46/EVOKE‑03 (Trodelvy + KEYTRUDA) in PD‑L1 ≥50% mNSCLC

eDMC recommended stopping the Phase 3 trial after final PFS and interim OS reviews: PFS trend non‑significant, OS unlikely to be significant; safety profile consistent; ~620 patients enrolled.

8 June 2026
Gilead and Merck: Phase 3 ISLEND trials show positive topline results for once‑weekly islatravir/lenacapavir

Once‑weekly oral islatravir 2 mg/lenacapavir 300 mg met Week 48 primary endpoint, non‑inferior to Biktarvy and daily standard‑of‑care; safety profile comparable across arms.

21 April 2026
FDA approves Merck’s IDVYNSO (doravirine/islatravir)

Once-daily, tenofovir-free two-drug regimen approved for virologically suppressed adults; Phase 3 non-inferior to BIC/FTC/TAF. Contraindicated with strong CYP3A inducers or 3TC/FTC; skin reactions.

19 November 2025
Merck Reports Positive Phase 3 Trial Results for HIV-1 Treatment DOR/ISL

DOR/ISL shows non-inferiority to BIC/FTC/TAF in HIV-1 treatment-naïve adults, meeting efficacy and safety goals. Detailed findings to be presented at a future scientific congress.